Home  |   About  |   Theory  |   Tutorials  |   FAQ  |   Bahar Lab  |   Statistics


Network of interactions between drugs (red spheres) and targets (blue spheres) is displayed above.
The red lines are used for the predicted interactions and the thickness of edges indicate the confidence score of predictions.

Data source: DrugBank-all; Query type: chemical; # of requested predictions: 20; Secondary interactions: no
Input drug 1: DB08889
No. Group Type Drug ID Drug Name SMILES
⇨ TargetHunter
1 Approved;
SmallMoleculeDrug DB08889 Carfilzomib Thumb

6 known interactions (targets) of input drug (DB08889): Carfilzomib
No. Gene UniProt ID Protein Name Pathway PDB
1 PSMB10 P40306 Proteasome subunit beta type-10 hsa03050 NA
2 PSMB9 P28065 Proteasome subunit beta type-9 hsa03050 NA
3 PSMB5 P28074 Proteasome subunit beta type-5 hsa03050 4R3O; 4R67
4 PSMB1 P20618 Proteasome subunit beta type-1 hsa03050 4R3O; 4R67
5 PSMB8 P28062 Proteasome subunit beta type-8 hsa03050 NA
6 PSMB2 P49721 Proteasome subunit beta type-2 hsa03050 4R3O; 4R67

20 predicted interactions (targets) of input drug (DB08889): Carfilzomib
No. Gene UniProt ID Protein Name Pathway PDB Confidence score
1 HTR1A P08908 5-hydroxytryptamine receptor 1A hsa04024; hsa04080; hsa04726; hsa04742 NA 38.6%
2 SRC P12931 Proto-oncogene tyrosine-protein kinase Src hsa01521; hsa01522; hsa04012; hsa04015; hsa04062; hsa04137; hsa04144; hsa04360; hsa04370; hsa04510; hsa04520; hsa04530; hsa04540; hsa04611; hsa04625; hsa04727; hsa04750; hsa04810; hsa04912; hsa04915; hsa04917; hsa04919; hsa04921; hsa04926; hsa05100; hsa05120; hsa05131; hsa05152; hsa05161; hsa05163; hsa05167; hsa05203; hsa05205; hsa05219; hsa05418 32.4%
3 DPP4 P27487 Dipeptidyl peptidase 4 hsa04974 30.0%
4 HAO1 Q9UJM8 Hydroxyacid oxidase 1 hsa00630; hsa01100; hsa01200; hsa04146 2NZL; 2RDT; 2RDU; 2RDW; 2W0U 28.4%
5 AHR P35869 Aryl hydrocarbon receptor hsa04659; hsa04934 NA 25.9%
6 PSMA6 P60900 Proteasome subunit alpha type-6 hsa03050 4R3O; 4R67 25.6%
7 FNTA P49354 Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha hsa00900 1JCQ; 1LD7; 1LD8; 1MZC; 1S63; 1SA4; 1TN6; 2F0Y; 2H6F; 2H6G; 2H6H; 2H6I; 2IEJ; 3E37 24.7%
8 PSMB3 P49720 Proteasome subunit beta type-3 hsa03050 4R3O; 4R67 24.7%
9 CSNK1G3 Q9Y6M4 Casein kinase I isoform gamma-3 hsa04340 2CHL; 2IZR; 2IZS; 2IZT; 2IZU; 4G16; 4G17; 4HGL; 4HGS 24.5%
10 NOS2 P35228 Nitric oxide synthase, inducible hsa00220; hsa00330; hsa01100; hsa04020; hsa04066; hsa04146; hsa04371; hsa04926; hsa05132; hsa05133; hsa05140; hsa05142; hsa05145; hsa05146; hsa05152; hsa05200; hsa05222 1NSI; 2LL6; 2NSI; 3E7G; 3EJ8; 3HR4; 4CX7; 4NOS 24.3%
11 PSMA4 P25789 Proteasome subunit alpha type-4 hsa03050 4R3O; 4R67 23.4%
12 ADH1C P00326 Alcohol dehydrogenase 1C hsa00010; hsa00071; hsa00350; hsa00830; hsa00980; hsa00982; hsa01100; hsa05204 1DDA; 1HT0; 1U3W 22.9%
13 CHRNB2 P17787 Neuronal acetylcholine receptor subunit beta-2 hsa04080; hsa04725; hsa05033 2GVT; 2K58; 2K59; 2KSR; 2LM2 22.0%
14 DRD3 P35462 D(3) dopamine receptor hsa04080; hsa04728 3PBL 21.8%
15 TUBB P07437 Tubulin beta chain hsa04145; hsa04540; hsa05130 3QNZ; 3QO0 21.3%
16 PSMB4 P28070 Proteasome subunit beta type-4 hsa03050 4R3O; 4R67 21.0%
17 HTR1B P28222 5-hydroxytryptamine receptor 1B hsa04024; hsa04080; hsa04726; hsa04742 2G1X; 4IAQ; 4IAR 20.8%
18 F11 P03951 Coagulation factor XI hsa04610 20.6%
19 PSMB6 P28072 Proteasome subunit beta type-6 hsa03050 4R3O; 4R67 20.5%
20 PSMA2 P25787 Proteasome subunit alpha type-2 hsa03050 4R3O; 4R67 20.5%


Reference:  Hongchun Li, Fen Pei, D. Lansing Taylor and Ivet Bahar. (2020) QuartataWeb: Integrated Chemical–Protein-Pathway Mapping for Polypharmacology and Chemogenomics. Bioinformatics 36(12), 3935–3937.


The QuartataWeb server is maintained by the Bahar Lab at the Department of Computational & Systems Biology at the University of Pittsburgh, School of Medicine, and sponsored by the NIH awards P41 GM103712 and P01 DK096990; and by the Li Lab at Research Center for Computer-Aided Drug Discovery at Shenzhen Institutes of Advanced Technology, CAS.

For questions and comments please contact Hongchun Li.